French hepatitis C care cascade: substantial impact of direct-acting antivirals, but the road to elimination is still long

Cécile Brouard (cecile.brouard@santepubliquefrance.fr)
Sante publique France, the national public health agency
https://orcid.org/0000-0001-9771-7400

Josiane Pillonel
Sante publique France

Marjorie Boussac
Caisse nationale de l'Assurance maladie

Victor de Lédinghen
Département Hospitalo-Universitaire de Pharmacologie de Bordeaux

Antoine Rachas
Caisse nationale de l'Assurance maladie

Christine Silvain
Centre hospitalo-universitaire de Poitiers

Nathalie Lydié
Sante publique France

Stéphane Chevaliez
Centre national de référence des hépatites B, C et Delta

Corinne Pioche
Sante publique France

Julien Durand
Sante publique France

Florence Lot
Sante publique France

Elisabeth Delarocque-Astagneau
Assistance Publique - Hopitaux de Paris

Research article

Keywords: hepatitis C, cascade of care, elimination, direct-acting antivirals, prevalence, diagnosis, management, treatment France

DOI: https://doi.org/10.21203/rs.3.rs-48545/v2

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: Hepatitis C virus (HCV) elimination by 2030, as targeted by the World Health Organization (WHO), requires that 90% of people with chronic infection be diagnosed and 80% treated. We estimated the cascade of care (CoC) for chronic HCV infection in mainland France in 2011 and 2016, before and after the introduction of direct-acting antivirals (DAAs).

Methods: The numbers of people (1) with chronic HCV infection, (2) aware of their infection, (3) receiving care for HCV and (4) on antiviral treatment, were estimated for 2011 and 2016. Estimates for 1) and 2) were based on modelling studies for 2011 and on a virological sub-study nested in a national cross-sectional survey among the general population for 2016. Estimates for 3) and 4) were made using the National Health Data System.

Results: Between 2011 and 2016, the number of people with chronic HCV infection decreased by 31%, from 192,700 (95% Credibility interval: 150,900-246,100) to 133,500 (95% Confidence interval: 56,900-312,600). The proportion of people aware of their infection rose from 57.7% to 80.6%. The number of people receiving care for HCV increased by 22.5% (representing 25.7% of those infected in 2016), while the number of people on treatment increased by 24.6% (representing 12.1% of those infected in 2016).

Conclusions: This study suggests that DAAs substantially impact CoC. However, access to care and treatment for infected people remained insufficient in 2016. Updating CoC estimates will help to assess the impact of new measures implemented since 2016 as part of the goal to eliminate HCV.

Introduction

With the advent of highly effective direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection, in 2014, the World Health Assembly pledged to eliminate HCV infection as a public health threat, through reducing new infections and deaths by 90% and 65%, respectively, by 2030 [1]. To achieve this, in 2016, the World Health Organization (WHO) launched a global strategy which aimed to diagnose 90% of people with HCV chronic infection and treat 80% of eligible patients by 2030 [2].

To monitor progress towards the WHO’s goal, evaluating the cascade of care (CoC) – a widely used tool for HIV infection [3] – may also be effective for HCV infection. This consists in estimating the numbers or percentages of infected people at various stages of the care pathway, from diagnosis to treatment. Identifying gaps in the CoC can help guide Public health policy. Although numerous studies have evaluated the HCV CoC using prospective or retrospective cohorts (i.e., a longitudinal approach), their samples comprised captive, often local, populations, including people attending screening or clinical centres [4, 5], which limits extrapolation of their results to the wider population. Evaluating the HCV CoC at a national level is essential, but challenging. It is often based on modelled data [6, 7] or on combining existing national data sometimes covering a large period of time [8-10]. However, the latter approach is not adapted to the rapidly evolving situation in the era of DAAs. Furthermore, published studies on the HCV CoC in the DAA era are scarce [7, 11, 12].

France has been involved for many years in the fight against hepatitis C, in particular through three national plans implemented since the end of the 1990s [13]. This has led to a slightly more favourable epidemiological situation than in most countries [14, 15], with an estimated viremic infection prevalence in mainland France in 2004 of 0.53% (95% Confidence Interval (CI): 0.40-0.70), corresponding to 232,000 chronically-infected individuals (95% CI: 167,869–296,523) in the 18-80 years old (y.o.) general population, and an estimated 57% (95% CI: 41-71) of these people being aware of their infection, corresponding to 132,000 (95% CI: 95,000-165,000) individuals [16]. Since then, HCV
screening activity has continuously increased, reaching 62 anti-HCV tests per 1,000 inhabitants in 2016 (vs. 53 / 1,000 in 2010) [17], despite no change in official screening recommendations for targeted people at risk of exposure. With regard to antiviral treatment, 1st and 2nd-wave DAAs have been rapidly and widely implemented in France, since 2011 and 2014, respectively, despite their restricted access for people with severe liver disease until mid-2016 [18]. In this favourable context, France has committed itself to achieving HCV elimination by 2025 [19].

National evaluations of the CoC for a given year are needed to monitor progress towards HCV elimination and to assess the impact of DAAs. Accordingly, in this study, we aimed to evaluate the CoC for chronic HCV in mainland France in 2011 and in 2016, before and after the introduction of 2nd-wave DAAs.

**Methods**

We used a cross-sectional approach to estimate chronic HCV CoC in 2011 and in 2016.

*Stages of the HCV cascade of care*

For both study years, we estimated the numbers of people 1) with chronic HCV infection, 2) aware of their infection, 3) receiving care for chronic HCV infection during the year, and 4) on antiviral treatment during the year. These numbers were estimated for the adult general population in mainland France aged 18-80 years for 2011, and 18-75 years for 2016 in the main analysis (the difference in age range being due to data sources, see below). A complementary analysis, incorporating age range adjustment, compared 18-80 years for 2016 with those from 2011.

The main data sources are summarized in Table 1 and presented below and in [20].

*Estimation of the numbers of people with chronic HCV infection and people aware of their infection*

For 2011

The number of people with HCV chronic infection was estimated using the multi-parameter evidence synthesis method (MPES) [21]. This work, published elsewhere [22], consisted in dividing the whole population aged 18-80 years into five subgroups: injecting and non-injecting drug users, transfusion recipients before 1992, immigrants and the rest of the population (Figure 1). For each subgroup, population size and HCV prevalence (HCV antibodies and HCV RNA) - determined from pre-existing estimates or estimated using available data - were used to obtain the number of infected people (additional file 1). The five different numbers were combined to estimate the total number of people with HCV chronic infection and the prevalence among the adult population in mainland France. A Bayesian model was used to pool these different data and their uncertainties. The distribution of the number of chronically infected people was estimated using Monte-Carlo simulations (n=80,000) and summarized using the median and 95% credible interval (CrI).

The number of people aware of their infection was obtained by subtracting the estimated number of people unaware of their infection from the estimated number of chronically infected people in 2011. The former number was estimated using projection modelling (described elsewhere [23]) from the 2004 national prevalence survey, a cross-sectional survey with biological samples and face-to-face interviews, in particular on HCV tests history [16]. Briefly, to estimate the number of people unaware of their infection in 2011, the epidemiologic model made projections from the estimated number of people unaware of their infection in 2004 (for each year, gender and age-group), taking into account mortality, HCV incidence and diagnosis rates (Figure 2). Model parameters are described in additional file 2. To include uncertainties of the model parameters, several scenarios were studied to estimate a plausible interval around the final estimate of the number of people unaware of their chronic infection.
For 2016

The numbers of people with chronic HCV infection and people aware of their infection were both estimated using the national cross-sectional 2016-Health Barometer (2016-HB), which is a telephone-based survey conducted in 2016 on a large random sample (n=20,032) of people from the general population in mainland France. A virological sub-study called BaroTest was nested in 2016-HB, and was conducted among participants aged 18-75. BaroTest used home-based blood self-sampling on dried blood spots (DBS). From these DBS, detection of HCV antibodies and HCV RNA (in case of anti-HCV-positive samples) was performed [24, 25].

The number of people with HCV chronic infection was estimated by extrapolating the estimated HCV RNA prevalence to all 18-75 y.o. in the general population in mainland France, using the 2016 estimated population figure from the French Institute for Statistics and Economic Studies (Insee) [26].

The proportion of people with chronic HCV infection aware of their status was defined as the proportion of people among those tested positive for HCV RNA in the BaroTest study, who reported - during the 2016-HB telephone interview - that they had been previously screened for HCV, and that the result of their last HCV test was positive. This proportion was then applied to the 2016 estimated population figure for 18-75 y.o. persons living in mainland France (Insee) [26] in order to estimate the number of people with HCV chronic infection aware of their infection.

More details on these estimates are provided in [24].

**Estimation of the numbers of people receiving care for chronic HCV infection and people on HCV antiviral treatment**

For 2011 and 2016, these estimates were performed using data from the French National Health Data System (SNDS) for all France's health insurance schemes. This health administrative database covers almost the entire French population [27, 28]. It contains individual data on all outpatient healthcare reimbursements (including drugs, biological tests, medical procedures), on hospitalizations in public and private hospitals (in particular admission and discharge dates, primary, related and associated diagnoses) and demographical data. All drugs dispensed in retail pharmacies (and reimbursed) and those dispensed in public and private hospitals (if they are on the list of expensive drugs, such as DAAs) are included. The SNDS also includes information on long-term diseases (LTD). Persons with LTD status in France are fully reimbursed for related healthcare expenditures. However, it does not contain any clinical information about the context of medical consultations, of drug prescriptions or examination results, including biological test results.

To identify people receiving care for chronic HCV infection using the SNDS, an algorithm was constructed in collaboration with clinical and technical experts on health administrative databases. Criteria were defined to identify patients at different stages of the care pathway (initial assessment, treatment etc.). Four successive versions of the algorithm were developed and their results were discussed with the two expert groups before the final algorithm (named “principal algorithm” hereafter) was implemented. We split criteria types into “major” (a high presumed specificity with regard to chronic hepatitis C), “intermediate” (intermediate presumed specificity), and “minor”, (low presumed specificity). Care for chronic HCV infection was defined as meeting either at least one major criterion or both the one designated intermediate criterion and at least one minor criterion. Because it was essential to identify people receiving care for chronic HCV infection, excluding people with resolved infection, we chose a very specific definition for the principal algorithm. To assess the impact of this specific definition on the results, an “alternative algorithm”, which was more sensitive, was constructed. These algorithms are presented in Table 2, and details about the various codes used for them are provided in additional file 3.
To estimate the number of persons on HCV antiviral treatment in 2011 and in 2016, people who had at least one reimbursement for pegylated interferon and ribavirin (with at least one common delivery date) or at least one reimbursement for first or second generation DAAs, were identified in the SNDS. Details are provided in [18] and in additional file 3.

**Analysis with age range adjustment**

In the main analysis, the estimation of chronic HCV CoC concerned 18-80 y.o. for 2011 and 18-75 y.o. for 2016, because of the data sources available to estimate the numbers of people with chronic HCV infection and people aware of their infection. To assess the impact of this difference in study age range on the evolution of the CoC between the two study years, the CoC was estimated for the 18-80 y.o. for 2016 in a complementary analysis which adjusted for the age range difference.

The additional number of persons with chronic HCV infection in the 76-80 y.o. in 2016 was estimated by applying the prevalence estimated in the 65-75 y.o. in the BaroTest study [24, 25] to the estimated population of 76-80 y.o. persons living in mainland France in 2016 (Insee) [26]. The total estimated number of persons with chronic HCV infection in the 18-80 y.o. in 2016 was then applied to the proportion of persons aware of their infection among the 18-75 y.o. estimated from the BaroTest, in order to calculate the total number of persons aware of their infection among 18-80 y.o. persons.

The numbers of people aged 18-80 receiving care and on antiviral treatment in 2016 were estimated from the analysis of SNDS data.

**Results**

The estimated numbers of people at the different stages of the chronic HCV CoC according to the main and age range-adjusted analyses, and their evolution between 2011 and 2016, are presented in Table 3. The corresponding CoC for both years are illustrated in Figure 3.

**Main analysis**

Between 2011 and 2016, chronic HCV infection prevalence decreased from 0.42% (95%CrI: 0.33-0.53) to 0.30% (95%CI: 0.13-0.70). The number of people with chronic HCV infection decreased by 30.8%, from 192,737 to 133,466. While the number of those aware of their infection remained stable (111,266 in 2011, 107,574 in 2016), the relative proportion of this sub-group rose from 57.7% to 80.6%.

In the same period, the numbers of people receiving care for chronic HCV infection and on antiviral treatment increased by 22.5% (from 28,026 to 34,345) and 24.6% (from 12,933 to 16,117), respectively. Between 2011 and 2016, their proportion among the people with chronic HCV infection increased from 14.5% to 25.7% and from 6.7% to 12.1%, respectively. Among people aware of their infection, 25.2% were receiving care for HCV chronic infection and 11.6% were on antiviral treatment in 2011, versus 31.9% and 15.0% in 2016, respectively.

The alternative algorithm, which was more sensitive, identified 31,371 people in care for chronic HCV infection in 2011 and 41,905 in 2016 (i.e., 11.9% and 19.7% additional persons, respectively, compared with the principal algorithm).

**Analysis with age range adjustment**
Taking into account the 76-80 y.o. in the 2016 CoC estimation led to an increase of 2.5% in both the number of people with chronic HCV infection and in people aware of their infection, 4.3% in the number of people receiving care, and 3.7% in the number of people on treatment.

In the age range-adjusted analysis, between 2011 and 2016, the decreases in the numbers of infected people and people aware of their infection were slightly lower than in the main analysis, while the increases in the numbers of people receiving care and people on treatment were higher (by approximately five percentage points) compared with the main analysis (Table 3).

Including the 76-80 year olds in the 2016 HCV CoC had little impact on the proportions of infected people at the different CoC stages compared with the main analysis (Figure 3).

Discussion

This work provides the first estimate of the French national CoC for chronic hepatitis C for two years, before and after the introduction of 2nd-wave DAAs, in the context of the goal to eliminate HCV. Between 2011 and 2016, the number of people with HCV chronic infection decreased by 30%, the proportion of people aware of their infection substantially increased (from 57.7% to 80.6%), and the numbers of people receiving care for HCV infection and on antiviral treatment during the year both increased by one quarter.

This work's has several strengths: first, it focused on the French population at the national level (i.e., not local or specific populations), enabling us to assess French progress toward the WHO's elimination objective [2]. Second, given the rapidly evolving situation in recent years, with the advent of DAAs in recent years, it provided estimates of the different stages of the CoC related to the same year (whether 2011 or 2016), not a larger period [8-10]. Third, almost all estimates of the numbers of people at the different stages were independently calculated. Estimates in some previous studies of national CoC [10, 29, 30] were interdependent, which could pose problems in the event of an error in one of the estimates. Fourth, SNDS data are not subject to selection bias because they cover almost the entire French population. Finally, by estimating the HCV CoC before (2011) and after (2016) the introduction of 2nd-wave DAAs, we were able to assess these drugs’ initial impact on the CoC.

Our work also has limitations: first, different methodologies were used to estimate the numbers of people with chronic HCV infection and those aware of their infection, specifically, modelling studies for 2011 [22, 23] and a cross-sectional survey (BaroTest) in the general population for 2016 [24]. In the latter type of survey, some populations at risk of HCV (e.g., active injecting drug users) are frequently not represented or are underrepresented, leading to possible underestimation of national prevalence. The difference we observed between 2011 and 2016 prevalence estimates is therefore probably overestimated. Second, given the low prevalence in the general population, the number of persons testing positive in BaroTest was small, leading to poor robustness in the estimated proportion of people aware of their infection in 2016 [24]. Third, because SNDS does not include biological test results or data on consultation diagnoses, we had to construct algorithms to identify people receiving HCV care. Validation studies would be necessary to assess these algorithms’ performance. Fourth, the identification of people on antiviral treatment depends on coding quality, which was suboptimal for DAAs in 2014-2015 but less so in 2016 [18, 31]. Finally, because of data sources, our CoC could not consider people older than 80 y.o. or those living in French overseas areas and could not be presented according to age, gender, at-risk exposures and time from infection (to focus on new or re-infected people).

The decrease in chronic hepatitis C prevalence (from 0.42% in 2011 to 0.30% in 2016) is probably mostly linked to highly effective 2nd-wave DAAs which led to at least 20,000 people in France being cured in 2014-2015 [18]. A
decrease in prevalence (from 1% to 0.6%) was also observed in a population-level CoC in British Columbia between 2012 and 2018 [11]. This trend can also be explained by deaths and aging in the HCV population beyond the age limit of the prevalence surveys (80 years for 2011, 75 years for 2016). Indeed, in France, a large percentage of HCV contaminations occurred before the implementation of systematic testing of blood donors and harm reduction measures in the 1990s, leading to a rather elderly population of people with chronic HCV infection. A continuation of the decrease in the incidence among people who actively inject drugs - observed between 2004 and 2011 (from 15.4 to 11.2 per 100 person-years) [32] - is another possible explanation.

The increasing trend in the proportion of chronically infected people aware of their infection observed in our study is coherent with other published estimates for France [6, 15, 33]. This trend may be partly explained by the substantial increase in anti-HCV screening activity in laboratories (+21% between 2010 and 2016) [17], which in turn is possibly related to the availability of DAAs and to experts’ recommendations in 2014 and 2016 advocating universal screening [14, 34]. In addition, the decrease in the number of elderly infected patients (whether through death or aging beyond the age limit of related studies), which constituted the age-group with the highest proportion of undiagnosed cases [23], may have contributed to the large observed increase in the proportion of people aware of their infection between 2011 and 2016.

The numbers of people receiving care for chronic HCV infection and on antiviral treatment during the year increased by 22.5% and 24.6%, respectively, between 2011 and 2016. As depicted in additional file 4, these numbers evolved in parallel with the advent of new antiviral drugs.

Our results show a substantial improvement in all the stages of the chronic HCV CoC over a short 5-year period, characterized by major therapeutic innovations, specifically the advent of 1\textsuperscript{st} and 2\textsuperscript{nd}-wave DAAs, which were rapidly and widely implemented in France [18].

In 2016, according to our estimates, among people with chronic HCV infection, more than eight in ten were aware of their infection, one in four received care for their HCV infection, and one in eight were on antiviral treatment during the year. Our results are relatively consistent with 2015 Markov model-based estimates by the European Union HCV Collaborators group which found that among chronically-infected people in France (estimated prevalence=0.29%), 74.1% were diagnosed and 10.2% started treatment [6]. Moreover, the group’s estimates for the European Union as a whole (estimated prevalence=0.64%) [6], were 36.7% and 7.5%, respectively, which highlights France’s favourable situation when compared with other countries in the European Union (4\textsuperscript{th} position for the diagnosis rate, and 2\textsuperscript{nd} position for the proportion of persons treated) [6], which is even more favourable when compared with the rest of the world (20% - diagnosis and 1.5% - newly treated) [35]. Since 2016, these figures have placed France on the short list of countries considered to be on track to eliminate hepatitis C by 2030 [36]. A recent modelling study projected that France will reach HCV elimination by 2024 [37]. Indeed, France has already met the eight criteria identified in the study for successful HCV elimination, in particular the following essential criteria: i) political will, ii) a financed “priority prevention” plan (in 2018 as a result of criterion i)) which aimed to achieve HCV elimination by 2025 [19]), iii) the removal of treatment restrictions in mid-2016 (which led to a 35% increase in the number of patients initiating a DAA treatment between 2016 and 2017 [31]), and iv) monitoring and evaluation of existing programs. The other criteria are: vi) the expansion of treatment provision beyond specialists (DAAs can be delivered in retails pharmacies since March 2017 and prescribed by all physicians since May 2019), vii) the implementation of an awareness campaign in the general population ("Noise against the Hepatitis C") [38], viii) a national screening program (annual local campaigns since 2019 and a national linkage to care program with outreach actions), and viii) the existence of harm-reduction programs (in particular, reinforced test and treat programs) [39].
Although it is expected that this comprehensive elimination program implemented in France in recent years will help enhance the country's HCV CoC, our results demonstrate that in 2016, France was still far from reaching WHO's elimination targets, in particular regarding the proportion of treated patients (only 12% versus the WHO objective of 80%) [2]. Our work highlights that care management for chronic HCV infection constitutes a major gap with an estimated 31.9% people receiving care among those aware of their infection in 2016. The choice of a conservative algorithm to identify people in care may partly explain this low proportion, which should be considered as a minimum. However, the application of the alternative, more sensitive algorithm led to a slightly increased proportion (38.2%). Universal access to DAAs in France (announced in mid-2016 but only effective since mid-2017), may further increase this proportion. The diagnosis of infected people also constitutes a challenge for HCV elimination. Experts and patient associations strongly advocated universal screening of all adults at least once during their lifetime, in addition to risk-based targeted testing [14, 34], after a modelling study showed that this new strategy could be cost-effective [40]. However, in 2019, the French National Authority for Health concluded that its effectiveness was not sufficiently demonstrated [41].

In conclusion, our study demonstrates a marked improvement in the CoC for chronic HCV infection between 2011 and 2016, suggesting the substantial impact of 2\textsuperscript{nd}-wave DAAs in mainland France. However, access to care and antiviral treatment remained insufficient in 2016, when considering the WHO’s elimination target of 2030. These national estimates will have to be updated to assess the impact of new measures implemented since 2016, and to monitor the elimination of HCV by 2025, as planned by France. Further studies are also needed to estimate the CoC among specific populations including people who inject drugs.

**Abbreviations**

CI: Confidence Interval

CrI: Credible interval

CoC: Cascade of care

DAAs: Direct-acting antivirals

DBS: Dried blood spots

HB: Health Barometer

HCV: Hepatitis C Virus

Insee: French Institute for Statistics and Economic Studies

LTD: long-term diseases

MPES: Multi-parameter evidence synthesis method

PCR: Polymerase chain reaction

RNA: Ribonucleic acid

SNDS: French National Health Data System

WHO: World Health Organization
Declarations

Ethics approval and consent to participate

For BaroTest survey, consent was obtained using a written informed consent. The research protocol was validated by the Committee for the protection of the persons (CPP), the French ethical committee for biomedical research (no. 2015-A01252-47).

Data from the SNDS used in this work received approval from the French data protection authority (CNIL: Commission nationale de l’informatique et des libertés) in October 2001. A ministerial order dated 1st December 2011 gave to accredited staff of the national public health agency access to SNDS anonymized individual data. The authors, who did the extraction and analysis, were accredited to SNDS database access.

Modelling methods used data that were previously published.

Consent for publication

Not applicable.

Available data and materials

All data generated or analysed during this study are included in this published article and its supplementary files.

Competing interests

Stéphane Chevaliez has received research grants from Gilead and has served as an advisor and/or speaker for Abbott, Cepheid, Hologic

Victor de Lédinghen has received consulting fees from Gilead, AbbVie.

Christine Silvain has served as a speaker for AbbVie, Gilead

None for the other authors.

Funding

None

Authors’ contributions

CB, JP and EDA conceived the design of this study. CB, NL, FL and SC conducted BaroTest survey. CB performed the data analysis of BaroTest survey, of the projection modelling (to estimate the number of people aware of their infection in 2011) and SNDS. MBZ, JD and AR contributed to SNDS data analysis and helped, with CS, VDL, JP, EDA and FL, in the interpretation of these data. CP performed data analysis using MPES to estimate the number of people with chronic HCV infection in 2011 with the contribution of CB, JP and FL. CB, JP and EDA interpreted the data with support from CS, VDL and FL. CB conducted the literature review and wrote the manuscript. All authors commented on the manuscript and approved the final version.

Acknowledgments

To all the people who contributed to producing the estimates used in this work: JC. Desenclos, A. Gautier, M. Jauffret-Roustage, C. Larsen, Y. Le Strat, C. Pelat, D. Rahib, JB. Richard, L. Saboni, C. Sommen (Santé publique France); F. Barin
(HIV National Reference Centre), C. Gastaldi-Ménager, T. Lesuffleur (Cnam) and the infectious work-group of the ReDSIAM.

To Jude Sweeney for the English revision of the manuscript.

References

[1] World Health Organization. Resolution of the 67th World Health Assembly on viral hepatitis (WHA 67.6). Geneva: World Health Organization; 2014. http://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_R6-en.pdf

[2] World Health Organization. Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis. Geneva: 2016. http://apps.who.int/iris/bitstream/10665/246177/1/WHO-HIV-2016.06-eng.pdf?ua=1

[3] Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52:793-800.

[4] Wade AJ, Macdonald DM, Doyle JS, Gordon A, Roberts SK, Thompson AJ, et al. The Cascade of Care for an Australian Community-Based Hepatitis C Treatment Service. PLoS One. 2015;10:e0142770.

[5] Patel RC, Vellozzi C, Smith BD. Results of Hepatitis C Birth-Cohort Testing and Linkage to Care in Selected U.S. Sites, 2012-2014. Public Health Rep. 2016;131 Suppl 2:12-9.

[6] European Union HCV Collaborators. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. The lancet Gastroenterology & hepatology. 2017;2:325-36.

[7] Chhatwal J, Chen Q, Bethea ED, Hur C, Spaulding AC, Kanwal F. The impact of direct-acting anti-virals on the hepatitis C care cascade: identifying progress and gaps towards hepatitis C elimination in the United States. Alimentary pharmacology & therapeutics. 2019;50:66-74.

[8] Yehia BR, Schranz AJ, Umscheid CA, Lo Re V, 3rd. The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PLoS One. 2014;9:e101554.

[9] Simmons R, Ireland G, Irving W, Hickman M, Sabin C, Ijaz S, et al. Establishing the cascade of care for hepatitis C in England-benchmarking to monitor impact of direct acting antivirals. J Viral Hepat. 2018;25:482-90.

[10] Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med. 2013;368:1859-61.

[11] Bartlett SR, Yu A, Chapinal N, Rossi C, Butt Z, Wong S, et al. The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: Impact of Direct Acting Antivirals. Liver international : official journal of the International Association for the Study of the Liver. 2019.

[12] Tsertsvadze T, Gamkrelidze A, Chkhartishvili N, Abutidze A, Sharvadze L, Kerashvili V, et al. Three years of progress towards achieving hepatitis C elimination in the country of Georgia, April 2015 - March 2018. Clin Infect Dis. 2019.

[13] Delarocque-Astagneau E, Meffre C, Dubois F, Pioche C, Le Strat Y, Roudot-Thoraval F, et al. The impact of the prevention programme of hepatitis C over more than a decade: the French experience. J Viral Hepat. 2010;17:435-43.
[14] Bottero J, Brouard C, Roudot-Thoraval F, Deuffic-Burban S, Hoflier P, Abergel A, et al. 2014 French guidelines for hepatitis B and C screening: a combined targeted and mass testing strategy of chronic viruses namely HBV, HCV and HIV. Liver international : official journal of the International Association for the Study of the Liver. 2016;36:1442-9.

[15] Deuffic-Burban S, Deltenre P, Buti M, Stroffolini T, Parkes J, Muhlberger N, et al. Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology. 2012;143:974-85.e14.

[16] Meffre C, Le Strat Y, Delarocque-Astagneau E, Dubois F, Antona D, Lemaisson JM, et al. Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors. J Med Virol. 2010;82:546-55.

[17] Pioche C, Léon L, Vaux S, Brouard C, Lot F. Dépistage des hépatites B et C en France en 2016, nouvelle édition de l'enquête LaboHep. Bull Epidemio Hebd. 2018:188-95.

[18] Brouard C, Boussac-Zarebska M, Silvain C, Durand J, de Ledinghen V, Pillonel J, et al. Rapid and large-scale implementation of HCV treatment advances in France, 2007-2015. BMC infectious diseases. 2017;17:784.

[19] Comité interministériel pour la santé. Priorité prévention : rester en bonne santé tout au long de sa vie, 2018-2022. 2018. https://solidarites-sante.gouv.fr/IMG/pdf/plan_national_de_sante_publique__psnp.pdf

[20] Brouard C. Cascade de prise en charge de l'hépatite C chronique en France métropolitaine [Thesis]: Université Paris-Saclay; 2019. 278 p. Available from: https://tel.archives-ouvertes.fr/tel-02434638/document

[21] Sweeting MJ, De Angelis D, Hickman M, Ades AE. Estimating hepatitis C prevalence in England and Wales by synthesizing evidence from multiple data sources. Assessing data conflict and model fit. Biostatistics (Oxford, England). 2008;9:715-34.

[22] Pioche C, Pelat C, Larsen C, Desenclos JC, Jauffret-Roustide M, Lot F, et al. Estimation de la prévalence de l'hépatite C en population générale, France métropolitaine, 2011. Numéro thématique. Hépatites B et C, données épidémiologiques récentes. Bull Epidemio Hebd. 2016:224-9.

[23] Brouard C, Le Strat Y, Larsen C, Jauffret-Roustide M, Lot F, Pillonel J. The undiagnosed chronically-infected HCV population in France. Implications for expanded testing recommendations in 2014. PLoS One. 2015;10:e0126920.

[24] Brouard C, Saboni L, Gautier A, Chevaliez S, Rahib D, Richard J-B, et al. HCV and HBV prevalence based on home blood self-sampling and screening history in the general population in 2016: contribution to the new French screening strategy. BMC infectious diseases. 2019.

[25] Lydie N, Saboni L, Gautier A, Brouard C, Chevaliez S, Barin F, et al. Innovative Approach for Enhancing Testing of HIV, Hepatitis B, and Hepatitis C in the General Population: Protocol for an Acceptability and Feasibility Study (BaroTest 2016). JMIR research protocols. 2018;7:e180.

[26] National Institute of Statistics and Economic Studies (INSEE). https://www.insee.fr/en/accueil

[27] Tuppin P, Rudant J, Constantinou P, Gastaldi-Menager C, Rachas A, de Roquefeuil L, et al. Value of a national administrative database to guide public decisions: From the systeme national d'information interregimes de l'Assurance Maladie (SNIIRAM) to the systeme national des donnees de sante (SNDS) in France. Revue d'epidemiologie et de sante publique. 2017;65 Suppl 4:S149-s67.
[28] Moulis G, Lapeyre-Mestre M, Palmaro A, Pugnet G, Montastruc JL, Sailler L. French health insurance databases: What interest for medical research? Rev Med Interne. 2015;36:411-7.

[29] <hivandhepatitis.com_AASLD_2013_Holmberg.pdf>.

[30] Papatheodoridis G, Sypsa V, Kantzanou M, Nikolakopoulos I, Hatzakis A. Estimating the treatment cascade of chronic hepatitis B and C in Greece using a telephone survey. J Viral Hepat. 2015;22:409-15.

[31] Dessauce C, Semenzato L, Rachas A, Barthélémy P, Lavin L, Comboroure J-C, et al. Les antiviraux à action directe dans le traitement de l’hépatite C chronique : retour sur quatre ans de prise en charge par l'Assurance maladie (janvier 2014-décembre 2017). Bull Epidemiol Hebd. 2019:502-9.

[32] Leon L, Kasereka S, Barin F, Larsen C, Weill-Barillet L, Pascal X, et al. Age- and time-dependent prevalence and incidence of hepatitis C virus infection in drug users in France, 2004-2011: model-based estimation from two national cross-sectional serosurveys. Epidemiology and infection. 2017;145:895-907.

[33] Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat. 2014;21 Suppl 1:34-59.

[34] Prise en charge thérapeutique et suivi de l'ensemble des personnes infectées par le virus de l'hépatite C. Rapport de recommandations 2016. Sous la direction du Professeur Daniel Dhumeaux et sous l’égide de l’ANRS et du CNS et avec le concours de l’AFEWF. 2016. http://social-sante.gouv.fr/IMG/pdf/rapport_.pdf

[35] World Health Organization. Global hepatitis report, 2017. World Health Organization; 2017. http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455-eng.pdf?ua=1

[36] Center for Disease Analysis Foundation. Just 12 countries worldwide on track to eliminate hepatitis C infection by 2030, with United Kigdom, Italy ans Spain among those joining the list. 2018. https://cdafound.org/just-12-countries-worldwide-on-track-to-eliminate-hepatitis-c-infection-by-2030-with-united-kingdom-italy-and-spain-among-those-joining-the-list/

[37] Razavi H, Sanchez Gonzalez Y, Yuen C, Comberg M. Global timing of hepatitis C virus elimination in high-income countries. Liver international : official journal of the International Association for the Study of the Liver. 2019.

[38] Association française pour l’étude du foie, SOS Hépatites. Du bruit contre l'hépatite C. https://dubruitcontrelhepatitec.com/

[39] Delile JM, de Ledinghen V, Jauffret-Roustide M, Roux P, Reiller B, Foucher J, et al. Hepatitis C virus prevention and care for drug injectors: the French approach. Hepatology, medicine and policy. 2018;3:7.

[40] Deuffic-Burban S, Huneau A, Verleene A, Brouard C, Pillonel J, Le Strat Y, et al. Assessing the cost-effectiveness of hepatitis C screening strategies in France. J Hepatol. 2018;69:785-92.

[41] Haute autorité de santé. Evaluation des stratégies de dépistage des personnes infectées par le virus de l’hépatite C (VHC) - Volet 1 Evaluer l'efficience des stratégies de dépistage. Saint-Denis: HAS; 2019. https://www.has-sante.fr/upload/docs/application/pdf/2019-09/evaluation_economique_evaluation_des_strategies_de_depistage_des_personnes_infectees_par_le_vhc_volet_1.pdf

Tables
### Table 1
Description of methodologies used for the estimation of the chronic HCV cascade of care in 2011 and 2016 in mainland France

| Estimation of the numbers of people | 2011                                           | 2016                                           |
|-------------------------------------|------------------------------------------------|------------------------------------------------|
| With chronic HCV infection         | Modelling using the multi-parameter evidence synthesis method | Cross-sectional survey (BaroTest)             |
| Aware of their infection           | Projection modelling                            | Cross-sectional survey (BaroTest)             |
| Receiving care for chronic HCV infection during the year | National Health Data System analysis            | National Health Data System analysis          |
| On antiviral treatment during the year | National Health Data System analysis            | National Health Data System analysis          |
Table 2
Algorithms (principal and alternative) to identify people receiving care for chronic HCV infection from the French National Health Data System

| Items                                                                 | Definitions                                                                 | Modifications compared with principal algorithm |
|----------------------------------------------------------------------|-----------------------------------------------------------------------------|--------------------------------------------------|
| AT LEAST ONE MAJOR CRITERION DURING THE YEAR AMONG THE FOLLOWING:    |                                                                             |                                                 |
| HCV genotyping                                                      | $\geq 1$ reimbursement                                                      |                                                 |
| HCV antiviral treatment                                              | $\geq 1$ reimbursement for pegylated interferon and ribavirin (with at least one common delivery date) or for first or second generation DAAs |                                                 |
| HCV RNA quantitative PCR                                            | $\geq 3$ reimbursements                                                     | $\geq 2$                                        |
| Hospitalization with a principal or related diagnosis of chronic hepatitis C | $\geq 1$ hospitalization with a principal or related diagnosis of chronic hepatitis C in medicine, surgery or obstetric services |                                                 |
| Long-term disease (LTD) registration for chronic hepatitis C (“incident patients”) | New LTD registrations for chronic hepatitis C                                |                                                 |
| OR                                                                  |                                                                             |                                                 |
| BOTH THE INTERMEDIATE CRITERION DURING THE YEAR:                     |                                                                             |                                                 |
| HCV RNA quantitative PCR                                            | 2 reimbursements                                                            | 1                                                |
| AND AT LEAST ONE MINOR CRITERION DURING THE YEAR AMONG THE FOLLOWING: |                                                                             | $\geq 2$                                        |
| Liver fibrosis assessment                                           | $\geq 1$ reimbursement for liver biopsy, fibrosis, liver stiffness measurement or blood biomarkers |                                                 |
| Long-term disease registration for chronic hepatitis C (“prevalent patients”) | Patients registered with LTD status, excluding those admitted during the year |                                                 |
| Hospitalization with an associated diagnosis of chronic hepatitis C  | $\geq 1$ hospitalization with an associated diagnosis of chronic hepatitis C in medicine, surgery or obstetric services |                                                 |

Details of selected codes are provided in supplementary material, Table 3
Table 3
Estimates of the numbers of persons at the different stages of the HCV chronic cascade of care in 2011 and 2016 in mainland France (main analysis and analysis with age range adjustment)

| Estimated numbers of people | Main analysis | Analysis with age range adjustment |
|-----------------------------|---------------|-----------------------------------|
|                             | 2011          | 2016                               | Evolution 2011 / 2016 | 2016 | Evolution 2011 / 2016 |
|                             | 18–80 years   | 18–75 years                        |                      | 18–80 years |                      |
| With chronic HCV infection | 192,737       | 133,466                            | -30.8%               | 136,839 | -29.0%               |
|                             | (95% CrI: 150,935 – 246,055) | (95% CI: 56,880 – 312,616) |                      |        |                      |
| Aware of their infection    | 111,266       | 107,574                            | -3.3%                | 110,292 | -0.9%                |
|                             | (plausible interval: 76,050–158,000) | (95% CI: 58,992 – 127,594) |                      |        |                      |
| Receiving care for chronic HCV infection during the year | 28,026       | 34,345                             | + 22.5%              | 35,806 | + 27.8%              |
|                             | (alternative algorithm: 31,371) | (alternative algorithm: 41,095) |                      |        |                      |
| On antiviral treatment during the year | 12,933       | 16,117                             | + 24.6%              | 16,716 | + 29.3%              |

CrI: Credible interval, CI: Confidence interval

Figures
Figure 1

Schematic overview of the principle of the multi-parameter evidence synthesis method in 2011. Pop. = population; prev. = prevalence.
Figure 2

Schematic overview of the projection modelling used to estimate the number of people unaware of their infection in 2011. Each year, individuals enter or leave the pool of the chronically-infected undiagnosed population.

Figure 3

Estimated chronic HCV cascade of care in 2011 and in 2016 in mainland France according to main analysis and analysis with age range adjustment. Note: Percentages are calculated from the estimated numbers of people with chronic HCV infection

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Additionalfile1.docx
- Additionalfile2.docx
- Additionalfile3.docx
- Additionalfile4.pdf